Different Responses to Drug Safety Screening Targets between Human Neonatal and Infantile Heart Tissue and Cardiac Bodies Derived from Human-Induced Pluripotent Stem Cells

Table 1

Patient characteristics.

Patient ID	Age (days/months)	Birth weight (g)	Diagnosis	Type of operation	Drugs	SpO2	Experiments
HLHS1	36/1.2	3250	HLHSMSAS	Norwood procedure	M, D	99	FFR
HLHS2	15/0.5	2690	HIAA + VSD	Norwood procedure	M, BB, F, S, D	90	RDA, E4031, FFR, ISO
HLHS3	69/2.3	2100	HLHS	Norwood procedure	BB, ASA, D	70	RDA
HLHS4	12/0.4	3900	HLHSMA + TAPVR	Norwood procedure	M, Mil, D	95	RDA, E4031, FFR, ISO
HLHS5	6/0.2	2570	HLHSMAAA	Norwood procedure	M	95	RDA, FFR, ISO
HLHS6	7/0.2	2800	HLHS	Norwood procedure	M, BB, S, D	95	RDA, FFR, ISO
HLHS7	2/0.1	2700	HLHS + MS + AS	Norwood procedure	M, D	90	RDA, FFR, ISO
TOF1	168/5.5	3950	TOF + PDA	TOF repair	BB	91	RDA, FFR, ISO
TOF2	170/5.6	3000	TOF	TOF repair	Nil	99	RDA, E4031
TOF3	198/6.5	3200	TOF	TOF repair	Sot	100	RDA, E4031, FFR, ISO
TOF4	164/5.4	3300	TOF	TOF repair	A, S, BB, ASA	72	FFR, ISO
TOF5	210/6.9	3850	PA + VSD	VSD closure, RV-PA-conduit	ASA, BB	80	RDA, E4031 + ISO, FFR, ISO
TOF6	178/5.8	1550	TOF + PDA	TOF repair, closure of PDA	BB	65	RDA, E4031 + ISO, FFR, ISO
TOF7	129/4.2	3250	TOF	TOF repair	Nil	99	RDA, E4031 + ISO, FFR
TOF8	155/5.1	3100	TOF	TOF repair	Nil	98	FFR
TOF9	212/7.0	2650	PA-VSD	VSD closure, RV-PA conduit	ASA	75	RDA, FFR
TOF10	165/5.5	2900	TOF	TOF repair	Nil	92	E4031

M: male; F: female; AS: aortic stenosis; IAA: interrupted aortic arch; HLHS: hypoplastic left heart syndrome; PA: pulmonary atresia; PDA: patent ductus arteriosus; TAPVR: total anomalous pulmonary venous return; TOF: tetralogy of Fallot; VSD: ventricular septal defect; A: ACE inhibitor; ASA: acetylsalicylic acid; BB: ß-blocker; D: dexamethasone; F: furosemide; P: prostaglandin E2; Mil: milrinone; S: spironolactone; Sot: sotalol; oxyhemoglobin saturation by pulse oximetry; FFR: force-frequency relationship; ISO: isoproterenol; RDA: rate-dependent action potential adaptation.